BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38348878)

  • 1. Discovery of Highly Potent Small-Molecule PD-1/PD-L1 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
    Xu Y; Du H; Guo W; Liu B; Yan W; Zhang C; Qin L; Huang J; Wang H; Wu S; Ren W; Zou Y; Wang J; Zhu Q; Xu Y; Gu H
    J Med Chem; 2024 Mar; 67(5):4083-4099. PubMed ID: 38348878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 4-phenyl-1H-indazole derivatives as novel small-molecule inhibitors targeting the PD-1/PD-L1 interaction.
    Xu C; Sun Z; Zhang X; Zang Q; Yang Z; Li L; Yang X; He Y; Ma Z; Chen J
    Bioorg Chem; 2024 Jun; 147():107376. PubMed ID: 38640722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Small-Molecule Inhibitors of PD-1/PD-L1 Interaction via Structural Simplification Strategy.
    Zhang H; Xia Y; Yu C; Du H; Liu J; Li H; Huang S; Zhu Q; Xu Y; Zou Y
    Molecules; 2021 Jun; 26(11):. PubMed ID: 34199417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel resorcinol biphenyl ether-based macrocyclic small molecules as PD-1/PD-L1 inhibitors with favorable pharmacokinetics for cancer immunotherapy.
    Yang Z; Liu Z; Xu C; Xu J; Liu T; He H; Li L; Ren Y; Chen J
    Bioorg Chem; 2023 Oct; 139():106740. PubMed ID: 37478546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances of biphenyl small-molecule inhibitors targeting PD-1/PD-L1 interaction in cancer immunotherapy.
    Chen R; Yuan D; Ma J
    Future Med Chem; 2022 Jan; 14(2):97-113. PubMed ID: 34870447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of Novel PD-L1 Small-Molecular Inhibitors with Potent
    Liu L; Zhang H; Hou J; Zhang Y; Wang L; Wang S; Yao Z; Xie T; Wen X; Xu Q; Dai L; Feng Z; Zhang P; Wu Y; Sun H; Liu J; Yuan H
    J Med Chem; 2024 Mar; 67(6):4977-4997. PubMed ID: 38465588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, and structure-activity relationship of PD-1/PD-L1 inhibitors with a benzo[d]isoxazole scaffold.
    Huang X; Chen H; Dai X; Xu M; Wang K; Feng Z
    Bioorg Med Chem Lett; 2021 Nov; 52():128403. PubMed ID: 34610423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of Novel Small Antitumor Compounds Inhibiting PD-1/PD-L1 Binding.
    Akiyama Y; Ashizawa T; Iizuka A; Ando T; Ishikawa Y; Kondou R; Miyata H; Maeda C; Kanematsu A; Sugino T; Yamaguchi K
    Anticancer Res; 2022 Nov; 42(11):5233-5247. PubMed ID: 36288869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncovering the colorectal cancer immunotherapeutic potential: Evening primrose (Oenothera biennis) root extract and its active compound oenothein B targeting the PD-1/PD-L1 blockade.
    Lee EJ; Kim YS; Kim JH; Woo KW; Park YH; Ha JH; Li W; Kim TI; An BK; Cho HW; Han JH; Choi JG; Chung HS
    Phytomedicine; 2024 Mar; 125():155370. PubMed ID: 38266440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of quinazoline derivatives as novel small-molecule inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction.
    Wang Y; Kun Huang ; Gao Y; Yuan D; Ling L; Liu J; Wu S; Chen R; Li H; Xiong Y; Liu H; Ma J
    Eur J Med Chem; 2022 Feb; 229():113998. PubMed ID: 34839997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of benzo[d]isothiazole derivatives as novel scaffold inhibitors targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) interaction through "ring fusion" strategy.
    Gao Y; Wang H; Shen L; Xu H; Deng M; Cheng M; Wang J
    Bioorg Chem; 2022 Jun; 123():105769. PubMed ID: 35405572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a new inhibitor targeting PD-L1 for cancer immunotherapy.
    Wang F; Ye W; Wang S; He Y; Zhong H; Wang Y; Zhu Y; Han J; Bing Z; Ji S; Liu H; Yao X
    Neoplasia; 2021 Mar; 23(3):281-293. PubMed ID: 33529880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and evaluation of PD-1/PD-L1 small-molecule inhibitors bearing a rigid indane scaffold.
    Cai S; Wang K; Qi Z; Ye K; Zhou X; Jiang S; Zhang K; Zhang X; Wang T
    Eur J Med Chem; 2023 Aug; 256():115468. PubMed ID: 37207535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving tumor sensitivity by the introduction of an ester chain to triaryl derivatives targeting PD-1/PD-L1.
    Zhang Y; Yin F; Luo Z; Li S; Li X; Wan S; Chen Y; Kong L; Wang X
    Eur J Med Chem; 2024 May; 271():116433. PubMed ID: 38678826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction.
    Fang L; Tian J; Zhang K; Zhang X; Liu Y; Cheng Z; Zhou J; Zhang H
    Bioorg Med Chem; 2021 Sep; 46():116370. PubMed ID: 34481337
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Novel PD-L1 Inhibitors That Induce the Dimerization, Internalization, and Degradation of PD-L1 Based on the Fragment Coupling Strategy.
    Wang K; Zhang X; Cheng Y; Qi Z; Ye K; Zhang K; Jiang S; Liu Y; Xiao Y; Wang T
    J Med Chem; 2023 Dec; 66(24):16807-16827. PubMed ID: 38109261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel, potent and selective small-molecule inhibitor of PD-1/PD-L1 interaction with robust in vivo anti-tumour efficacy.
    Liu C; Zhou F; Yan Z; Shen L; Zhang X; He F; Wang H; Lu X; Yu K; Zhao Y; Zhu D
    Br J Pharmacol; 2021 Jul; 178(13):2651-2670. PubMed ID: 33768523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of CBPA as a New Inhibitor of PD-1/PD-L1 Interaction.
    Wang F; Ye W; He Y; Zhong H; Zhu Y; Han J; Gong X; Tian Y; Wang Y; Wang S; Ji S; Liu H; Yao X
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.